69 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
aimed at educating healthcare providers about TCR T-cell therapy in solid tumors, including synovial sarcoma, and the role of biomarkers and testing
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
funded healthcare program or (iii) otherwise subject to any governmental sanction in any jurisdiction (including disqualification from participation
8-K
EX-99.1
qgdyv4se4i3m3
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
8-K
1qbuj308a1
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
424B3
vzadqjco
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
nbc2z75 pjlhs6zqt
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
jgn rweu2
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-10.01
pvtz2gy
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
EX-99.1
p8ss3cg
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
EX-10.1
roemew74
16 Dec 20
Departure of Directors or Certain Officers
5:01pm